{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:17:07Z","timestamp":1793812627678,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014589","name":"Chief Scientist Office","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014589","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Stem Cell"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.stem.2026.04.016","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:57:30Z","timestamp":1779721050000},"page":"1098-1109.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Autologous macrophage therapy increases transplant-free survival in cirrhosis: Long-term follow-up of a phase 2 clinical trial"],"prefix":"10.1016","volume":"33","author":[{"given":"Paul N.","family":"Brennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair M.","family":"Kilpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Glover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc L.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Lachlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A.","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.stem.2026.04.016_bib1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/14728214.2021.1918099","article-title":"Emerging synthetic drugs for the treatment of liver cirrhosis","volume":"26","author":"Fallowfield","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.stem.2026.04.016_bib3","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jhep.2017.10.020","article-title":"Clinical states of cirrhosis and competing risks","volume":"68","author":"D\u2019Amico","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII \u2013 Renewing consensus in portal hypertension","volume":"76","author":"De Franchis","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib5","article-title":"Mechanisms and implications of recompensation in cirrhosis","volume":"6","author":"Piano","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.stem.2026.04.016_bib6","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1002\/hep.24315","article-title":"Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function","volume":"53","author":"Thomas","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.stem.2026.04.016_bib7","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.jcyt.2015.07.016","article-title":"Phenotypic and functional characterization of macrophages with therapeutic potential generated from human cirrhotic monocytes in a cohort study","volume":"17","author":"Moore","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2026.04.016_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41536-017-0017-0","article-title":"Injection of embryonic stem cell derived macrophages ameliorates fibrosis in a murine model of liver injury","volume":"2","author":"Haideri","year":"2017","journal-title":"NPJ Regen. Med."},{"key":"10.1016\/j.stem.2026.04.016_bib9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jhep.2020.02.031","article-title":"Alternatively activated macrophages promote resolution of necrosis following acute liver injury","volume":"73","author":"Starkey Lewis","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib10","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/s41591-019-0599-8","article-title":"Safety profile of autologous macrophage therapy for liver cirrhosis","volume":"25","author":"Moroni","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2026.04.016_bib11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41591-024-03406-8","article-title":"Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial","volume":"31","author":"Brennan","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2026.04.016_bib12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-025-03490-4","article-title":"Not the end of the road for macrophage therapy in liver cirrhosis","volume":"31","author":"Maher","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2026.04.016_bib13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/ajg.2015.191","article-title":"Causes of death in people with liver cirrhosis in England compared with the general population: a population-based cohort study","volume":"110","author":"Ratib","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.stem.2026.04.016_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000194","article-title":"Cause-specific mortality among patients with cirrhosis in a population-based cohort study in Ontario (2000\u20132017)","volume":"7","author":"Wang","year":"2023","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.stem.2026.04.016_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s41043-025-01109-5","article-title":"Global burden of liver cirrhosis: trends from 1990\u20132021 and projections to 2060","volume":"44","author":"Luo","year":"2025","journal-title":"J. Health Popul. Nutr."},{"key":"10.1016\/j.stem.2026.04.016_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/lt.24462","article-title":"Liver transplantation in the United Kingdom","volume":"22","author":"Neuberger","year":"2016","journal-title":"Liver Transplant."},{"key":"10.1016\/j.stem.2026.04.016_bib17","unstructured":"NHS Blood and Transplant. (2025). Annual Report on Liver Transplantation 2024\/2025. https:\/\/nhsbtdbe.blob.core.windows.net\/umbraco-assets-corp\/37114\/nhsbt-liver-transplantation-report-2425.pdf."},{"key":"10.1016\/j.stem.2026.04.016_bib18","unstructured":"U.S. Food and Drug Administration. (2019). Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/nonalcoholic-steatohepatitis-compensated-cirrhosis-developing-drugs-treatment-guidance-industry."},{"key":"10.1016\/j.stem.2026.04.016_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jhep.2005.01.019","article-title":"Evaluation of the increase in model for end-stage liver disease (\u0394MELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child\u2013Turcotte\u2013Pugh score","volume":"42","author":"Huo","year":"2005","journal-title":"J. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib20","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2025.12.008","article-title":"High Heterogeneity of Several Liver Histology Parameters in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease Demonstrated by Biopsies From 7 Segments","author":"Karlgren","year":"2025","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib22","article-title":"Prediction of major liver-related events in the population using prognostic models","volume":"13","author":"\u00c5berg","year":"2025","journal-title":"Gastroenterol. Rep. (Oxf.)"},{"key":"10.1016\/j.stem.2026.04.016_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2026.101746","article-title":"Fibrosis activity vs. disease stage: Complementary and independent predictors of outcomes in alcohol-related liver disease","volume":"8","author":"Johansen","year":"2026","journal-title":"JHEP Reports"},{"key":"10.1016\/j.stem.2026.04.016_bib24","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41575-021-00520-7","article-title":"Cirrhosis-associated immune dysfunction","volume":"19","author":"Albillos","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib25","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jhep.2021.01.018","article-title":"New clinical and pathophysiological perspectives defining the trajectory of cirrhosis","volume":"75","author":"Jalan","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1478-3231.2004.0894.x","article-title":"Serum levels of tumor necrosis factor-\u03b1 correlate with severity of hepatic encephalopathy due to chronic liver failure","volume":"24","author":"Odeh","year":"2004","journal-title":"Liver Int."},{"key":"10.1016\/j.stem.2026.04.016_bib27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"\u03b2 blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.stem.2026.04.016_bib28","article-title":"Progressive systemic inflammation precedes decompensation in compensated cirrhosis","volume":"7","author":"S\u00e1nchez-Aldehuelo","year":"2025","journal-title":"JHEP Rep."},{"key":"10.1016\/j.stem.2026.04.016_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ebiom.2018.01.028","article-title":"IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal","volume":"29","author":"Weng","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.stem.2026.04.016_bib30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.kint.2016.08.020","article-title":"IL-4\/IL-13\u2013mediated polarization of renal macrophages\/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury","volume":"91","author":"Zhang","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.stem.2026.04.016_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111045","article-title":"MMP10 alleviates non-alcoholic steatohepatitis by regulating macrophage M2 polarization","volume":"124","author":"Chang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.stem.2026.04.016_bib32","article-title":"IL-7 in autoimmune diseases: mechanisms and therapeutic potential","volume":"16","author":"Zeng","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2026.04.016_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1736931","article-title":"IL-7: a potential next-generation adjuvant for immune cell therapies","volume":"16","author":"Hotchkiss","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2026.04.016_bib34","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1053\/j.gastro.2024.08.046","article-title":"Immune Dysfunction and Infection Risk in Advanced Liver Disease","volume":"168","author":"McGettigan","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.stem.2026.04.016_bib35","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/MCG.0000000000000207","article-title":"Serum Albumin Can Identify Patients With Compensated Cirrhosis With a Good Prognosis","volume":"49","author":"Ripoll","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.stem.2026.04.016_bib36","first-page":"A57.2","article-title":"P68 An open-label phase 1\/2 multicentre study to evaluate the safety, tolerability and efficacy of RTX001 autologous macrophages in participants with liver cirrhosis who have hepatic decompensation (EMERALD)","volume":"74","author":"Fallowfield","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.stem.2026.04.016_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41536-025-00393-3","article-title":"Cryopreserved human alternatively activated macrophages promote resolution of acetaminophen-induced liver injury in mouse","volume":"10","author":"Candela","year":"2025","journal-title":"npj Regen. Med."},{"key":"10.1016\/j.stem.2026.04.016_bib38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41575-023-00796-x","article-title":"Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach","volume":"20","author":"Brennan","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70511","article-title":"Progression to Decompensation of Severe Fibrosis Compared to Cirrhosis in MASLD: A Systematic Review and Meta-Analysis","volume":"46","author":"Barrett","year":"2026","journal-title":"Liver Int."},{"key":"10.1016\/j.stem.2026.04.016_bib40","article-title":"Non-invasive tests: Establishing efficacy for metabolic dysfunction-associated steatohepatitis beyond the biopsy\u2014Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration","author":"Anania","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.stem.2026.04.016_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A Proportional Hazards Model for the Subdistribution of a Competing Risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.stem.2026.04.016_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting Linear Mixed-Effects Models Using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Soft."},{"key":"10.1016\/j.stem.2026.04.016_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v082.i13","article-title":"lmerTest Package: Tests in Linear Mixed Effects Models","volume":"82","author":"Kuznetsova","year":"2017","journal-title":"J. Stat. Soft."},{"key":"10.1016\/j.stem.2026.04.016_bib44","series-title":"Modern Applied Statistics with S","author":"Venables","year":"2002"},{"key":"10.1016\/j.stem.2026.04.016_bib45","series-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2001"},{"key":"10.1016\/j.stem.2026.04.016_bib46","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.stem.2026.04.016_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053190","article-title":"Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)","volume":"11","author":"Brennan","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.stem.2026.04.016_bib48","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/flgastro-2023-102430","article-title":"British Society of Gastroenterology Best Practice Guidance: outpatient management of cirrhosis \u2013 part 1: compensated cirrhosis","volume":"14","author":"Mansour","year":"2023","journal-title":"Frontline Gastroenterol."},{"key":"10.1016\/j.stem.2026.04.016_bib49","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","author":"Angeli","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib50","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/hep.30489","article-title":"Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases","volume":"69","author":"Kanwal","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.stem.2026.04.016_bib51","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/TP.0b013e318225db4d","article-title":"Elective Liver Transplant List Mortality: Development of a United Kingdom End-Stage Liver Disease Score","volume":"92","author":"Barber","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.stem.2026.04.016_bib52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","author":"Sangro","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.stem.2026.04.016_bib53","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.jcyt.2017.05.009","article-title":"Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis","volume":"19","author":"Fraser","year":"2017","journal-title":"Cytotherapy"}],"container-title":["Cell Stem Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1934590926001566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1934590926001566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:29:45Z","timestamp":1783006185000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1934590926001566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1934590926001566"],"URL":"https:\/\/doi.org\/10.1016\/j.stem.2026.04.016","relation":{},"ISSN":["1934-5909"],"issn-type":[{"value":"1934-5909","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous macrophage therapy increases transplant-free survival in cirrhosis: Long-term follow-up of a phase 2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"Cell Stem Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.stem.2026.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}